RT Journal Article
T1 Etiology of tricuspid regurgitation and mortality: a multicenter cohort study
A1 Rodríguez Capitán, Jorge
A1 Márquez‑Camas, Paloma
A1 Carmona‑Carmona, Jesús
A1 Arroyo Moñino, Diego Félix
A1 Chaparro‑Muñoz, Marinela
A1 Soler‑González, Matías
A1 García del Río, Manuel
A1 Egido de la Iglesia, Teodora
A1 Segovia‑Reyes, Jorge
A1 Murri, Mora
A1 López Salguero, José Raúl
A1 Couto‑Mallón, David
A1 Romero‑Cuevas, Miguel
A1 Pavón-Morón, Francisco Javier
A1 Gutiérrez-Bedmar, Mario
A1 Jiménez‑Navarro, Manuel
K1 Cardiología
K1 Válvula tricúspide
K1 Pronóstico médico
AB Background Significant tricuspid regurgitation (TR) encompasses a wide range of etiologies, complicating a comprehensive understanding of disease progression and prognostic factors. This study aimed to assess mortality associated with significant TR, focusing on the role of valvular disease etiology and other predictive factors. Methods This is a retrospective, multicenter, cohort observational study, including all consecutive patients with moderate-to-severe or greater TR. The patients were classified into five etiological groups: organic TR, TR secondary to left valvu-lopathy, TR secondary to left or right ventricular dysfunction, TR secondary to pulmonary hypertension, and atrial TR. The long-term mortality was assessed (median follow-up: 39.8 months). Results 757 patients were included. The overall mortality incidence rate was 162.5 deaths per 1000 patient-years. Compared to atrial TR, all other etiologies presented a higher mortality risk: organic TR adjusted hazard ratio (aHR) = 2.344 (95% confidence interval [CI]: 1.138–4.829), left valvulopathy-related TR aHR = 1.901 (95% CI: 1.011–3.574), ventricular dysfunction-related TR aHR = 3.683 (95% CI: 1.627–8.338), and pulmonary hypertension-related TR aHR = 2.446 (95% CI: 1.215–4.927). In addition to known factors, male sex was associated with a higher mortality risk (aHR = 1.608, 1.175–2.201),while beta-blocker use was linked to a lower risk (aHR = 0.674, 0.502–0.904).Conclusions In a large cohort of patients with significant TR, and after adjusting for clinical and echocardiographic variables, all etiological groups exhibited a higher mortality risk compared to atrial TR. Additionally, male patients with TRhad a higher mortality risk, while beta-blocker therapy emerged as a protective factor.
PB Springer Nature
YR 2025
FD 2025
LK https://hdl.handle.net/10630/38607
UL https://hdl.handle.net/10630/38607
LA eng
NO Rodríguez-Capitán, J., Márquez-Camas, P., Carmona-Carmona, J. et al. Etiology of tricuspid regurgitation and mortality: a multicenter cohort study. Clin Res Cardiol (2025). https://doi.org/10.1007/s00392-025-02662-z
NO Funding for open access charge: Universidad de Málaga/CBUA.  This research was supported by the Andalusian Society of Cardiology (General Research Grants, 2019). M.M. is sup- ported by Miguel Servet II program (CPII22-00013) from ISCIII and co-funded by the European Union, and by Nicolás Monardes Program from Consejería de Salud de Andalucía, Spain (C10002-2022) the pro- ject “PI23/00293” from ISCIII and co-funded by the European Union
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026